<code id='272FE12448'></code><style id='272FE12448'></style>
    • <acronym id='272FE12448'></acronym>
      <center id='272FE12448'><center id='272FE12448'><tfoot id='272FE12448'></tfoot></center><abbr id='272FE12448'><dir id='272FE12448'><tfoot id='272FE12448'></tfoot><noframes id='272FE12448'>

    • <optgroup id='272FE12448'><strike id='272FE12448'><sup id='272FE12448'></sup></strike><code id='272FE12448'></code></optgroup>
        1. <b id='272FE12448'><label id='272FE12448'><select id='272FE12448'><dt id='272FE12448'><span id='272FE12448'></span></dt></select></label></b><u id='272FE12448'></u>
          <i id='272FE12448'><strike id='272FE12448'><tt id='272FE12448'><pre id='272FE12448'></pre></tt></strike></i>

          leisure time

          leisure time

          author:Wikipedia    Page View:39458
          James Comer (R-KY) walks on the House side of the U.S. Capitol on May 14, 2024 in Washington, DC
          Rep. James Comer (R-Ky.), the chair of the House Committee on Oversight and Accountability, has taken an interest in pharmacy benefit managers. Kent Nishimura/Getty Images

          WASHINGTON — Executives from the three major pharmacy benefit manager companies have been invited to testify before the House Committee on Oversight and Accountability next month, four sources familiar with the planning told STAT.

          Executives from Optum, CVS Caremark, and Express Scripts, owned by Cigna, were asked to testify before the panel on June 4.

          advertisement

          The committee and companies did not respond to requests for comment.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          knowledge

          Apple is now the first public company to be valued at $3 trillion
          Apple is now the first public company to be valued at $3 trillion

          6:09FILE-AnApplelogoadornsthefacadeofthedowntownBrooklynApplestoreonMarch14,2020,inNewYork.Applebeca

          read more
          Prosecutors say FTX founder Sam Bankman
          Prosecutors say FTX founder Sam Bankman

          FILE-FTXfounderSamBankman-FriedleavesManhattanfederalcourtinNewYork,Feb.16,2023.Bankman-Friedisharas

          read more
          Jerome Adams on the need for new antivirals for Covid
          Jerome Adams on the need for new antivirals for Covid

          PaxlovidtabletsamplesbeinginspectedinFreiburg,Germany.PfizerviaAPTheU.S.Covid-19Public HealthEmergen

          read more

          Tocagen's brain cancer gene therapy trial continues. Investors worry

          MichelleMonje/StanfordUniversity/NIHTocagen(TOCA)saidTuesdaythataPhase3clinicaltrialinvolvinganovelg